Evidence map›Paper›PMID 36374469›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Zebrafish: A Tractable Model for Analysis of T Cell Development.

Robert Sertori, Yong Zhang, David L Wiest

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Robert SertoriBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Yong ZhangBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
David L WiestBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA. David.Wiest@FCCC.edu.
Fox Chase Cancer Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8M
Inherited T cell defects: Diagnosis, Mechanisms and TreatmentsP01AI138962 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRENNER, STEVEN E · 2020 to 2024
$11.3M
Regulation of hematopoiesis by ribosomal protein paralogsR37AI110985 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI DAVID L. WIEST · 2020 to 2026
$4.2M
NCI NIH HHS P30 CA006927NIAID NIH HHS P01 AI138962NIAID NIH HHS R37 AI110985
6 · The paper itself

Abstract

While the zebrafish has for some time been regarded as a powerful model organism with which to study early events in hematopoiesis, recent evidence suggests that it also ideal for unraveling the molecular requirements for T cell development in the thymus. Like mammals, zebrafish possess an adaptive immune system, comprising B lymphocytes as well as both the γδ and αβ lineages of T cells, which develop in the thymus. Moreover, the molecular processes underlying T cell development in zebrafish appear to be remarkably conserved. Thus, findings in the zebrafish model will be of high relevance to the equivalent processes in mammals. Finally, molecular processes can be interrogated in zebrafish far more rapidly than is possible in mammals because the zebrafish possesses many unique advantages. Here, we describe these unique attributes and the methods by which they can be exploited to investigate the role of novel genes in T cell development.

Indexed as

HematopoiesisZebrafishAnimalsCell DifferentiationMammalsT-LymphocytesFunctional rescueIn situ hybridizationMorpholinoT cell developmentZebrafish

Identifiers

PMID36374469
OpenAlexW4309001834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.